In particular, emerging pharmacotherapeutics—such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor (GLP-1R) agonists, including dual agonists targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIPR/GLP-1R)—may offer a dual benefit by managing diabetes and relieving HF symptoms in obese patients. The gene discussed is GIPR; the disease is hydrops fetalis.